<DOC>
	<DOCNO>NCT01761123</DOCNO>
	<brief_summary>purpose study determine safety tolerability VXA-A1.1 , adjuvanted adenoviral base influenza vaccine , delivery target ileum , use radio control capsule . The secondary objective evaluate immune response ( cellular humoral ) two dose VXA-A1.1 oral vaccine .</brief_summary>
	<brief_title>Immunogenicity Seasonal Influenza Delivery Directly Ileum</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Able willing complete inform consent Healthy , establish medical history , physical exam , laboratory assessment Has normal bowel movement Willing abstain caffeine xanthine contain substance 24 hour procedure discharge Not able donate 550 ml blood several month Exposure investigational drug vaccine 8 week prior study Abnormal ECG finding History irritable bowl inflammatory gastrointestinal disorder Any individual increase risk bowl obstruction Radiation exposure target value 50 mSv within past 30 day cumulative dose 150 mSV past 12 month History substance abuse Subject unwilling use approve method contraception study 2 month study Positive HCV , HIV , HBV Presence implantable device sensitive radio frequency ( e.g . pacemaker ) History autoimmune disorder , immunosuppressive disorder Stool sample occult blood baseline Any medical , psychiatric , social condition , occupation , judgement investigator contraindication compliance protocol inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prevention Influenza</keyword>
</DOC>